Browsing by Author "Demirkaya, Erkan"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Publication
    The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS
    (2022) Gedik, Kader; Lamot, Lovro; Romano, Micol; Demirkaya, Erkan; Piskin, David; Torreggiani, Sofia; Adang, Laura; Armangue, Thais; Barchus, Kathe; Cordova, Devon; Crow, Yanick; Dale, Russell; Durrant, Karen; Eleftheriou, Despina; Fazz, Elisa; Gattorno, Marco; Gavazzi, Francesco; Hanson, Eric; Lee-Kirsch, Min Ae; Montealegre, Gina; Neven, Bénédicte; Orcesi, Simona; Ozen, Seza; Poli Harlowe, María Cecilia; Schumacher, Elliot; Tonduti, Davide; Uss, Katsiaryna; Aletaha, Daniel; Feldman, Brian; Vanderver, Adeline; Brogan, Paul; Goldbach, Raphaela
    Objective: Autoinflammatory type I interferonopathies, chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature/proteasome-associated autoinflammatory syndrome (CANDLE/PRAAS), stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy (SAVI) and Aicardi-Goutières syndrome (AGS) are rare and clinically complex immunodysregulatory diseases. With emerging knowledge of genetic causes and targeted treatments, a Task Force was charged with the development of 'points to consider' to improve diagnosis, treatment and long-term monitoring of patients with these rare diseases. Methods: Members of a Task Force consisting of rheumatologists, neurologists, an immunologist, geneticists, patient advocates and an allied healthcare professional formulated research questions for a systematic literature review. Then, based on literature, Delphi questionnaires and consensus methodology, 'points to consider' to guide patient management were developed. Results: The Task Force devised consensus and evidence-based guidance of 4 overarching principles and 17 points to consider regarding the diagnosis, treatment and long-term monitoring of patients with the autoinflammatory interferonopathies, CANDLE/PRAAS, SAVI and AGS. Conclusion: These points to consider represent state-of-the-art knowledge to guide diagnostic evaluation, treatment and management of patients with CANDLE/PRAAS, SAVI and AGS and aim to standardise and improve care, quality of life and disease outcomes.
  • Thumbnail Image
    Item
    The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology Points to Consider for Diagnosis and Management of Autoinflammatory Type I Interferonopathies: CANDLE/PRAAS, SAVI, and AGS
    (2022) Gedik, Kader Cetin; Lamot, Lovro; Romano, Micol; Demirkaya, Erkan; Piskin, David; Torreggiani, Sofia; Adang, Laura A.; Armangue, Thais; Barchus, Kathe; Cordova, Devon R.; Crow, Yanick J.; Dale, Russell C.; Durrant, Karen L.; Eleftheriou, Despina; Fazzi, Elisa M.; Gattorno, Marco; Gavazzi, Francesco; Hanson, Eric P.; Lee-Kirsch, Min Ae; Montealegre Sanchez, Gina A.; Neven, Bénédicte; Orcesi, Simona; Ozen, Seza; Poli, Cecilia; Schumacher, Elliot; Tonduti, Davide; Uss, Katsiaryna; Aletaha, Daniel; Feldman, Brian M.; Vanderver, Adeline; Brogan, Paul A.; Goldbach-Mansky, Raphaela
    Objective.Autoinflammatory type I interferonopathies, chronic atypical neutrophilic dermatosis with lipodystrophyand elevated temperature/proteasome-associated autoinflammatory syndrome (CANDLE/PRAAS), stimulator of inter-feron genes (STING)–associated vasculopathy with onset in infancy (SAVI), and Aicardi-Goutières syndrome (AGS) arerare and clinically complex immunodysregulatory diseases. With emerging knowledge of genetic causes and targetedtreatments, a Task Force was charged with the development of“points to consider”to improve diagnosis, treatment,and long-term monitoring of patients with these rare diseases.Methods.Members of a Task Force consisting of rheumatologists, neurologists, an immunologist, geneticists,patient advocates, and an allied health care professional formulated research questions for a systematic literaturereview. Then, based on literature, Delphi questionnaires, and consensus methodology,“points to consider”to guidepatient management were developed.Results.The Task Force devised consensus and evidence-based guidance of 4 overarching principles and17 points to consider regarding the diagnosis, treatment, and long-term monitoring of patients with the autoinflamma-tory interferonopathies, CANDLE/PRAAS, SAVI, and AGS.Conclusion.These points to consider represent state-of-the-art knowledge to guide diagnostic evaluation, treat-ment, and management of patients with CANDLE/PRAAS, SAVI, and AGS and aim to standardize and improve care,quality of life, and disease outcomes.

Implementado por OpenGeek Services